Hyperbaric oxygen therapy for long COVID: a prospective registry.

Hyperbaric oxygen therapy for long COVID: a prospective registry.

Publication date: Aug 04, 2025

A potential beneficial effect of hyperbaric oxygen therapy (HBOT) on complaints of long COVID was found, leading to increased demand for this treatment despite many remaining clinical questions and lack of formal guideline recommendations and reimbursement. A registry was set up in order to gain more insight into patient characteristics and (long-term) outcomes of long COVID patients undergoing HBOT. Patient-reported outcome measures were collected at baseline, after treatment, at 3-month and 1-year follow up. This publication includes the 3-month results. The primary outcome measures were the mental and physical component score (MCS/PCS) of the SF-36 questionnaire. A clinically relevant positive or negative response was defined as a ≥ 10 point increase or decrease of in MCS and/or PCS after 3 months. Secondary outcomes included the EQ-5D, severity of complaints and ability to work. In this prospective registry, 56-63% of long term-ill patients had a clinically relevant improvement in MCS/PCS 3 months after HBOT. However, 13-19% of the patients had a clinically relevant deterioration in MCS/PCS. Symptoms that showed most improvement were predominantly in the cognitive domain. This indicates that HBOT may have a positive effect on complaints of long COVID, but alertness for worsening of the condition should be exercised.

Open Access PDF

Concepts Keywords
Hbot Adult
Hyperbaric Aged
Month COVID-19
Primary Female
Therapy Humans
Hyperbaric Oxygenation
Male
Middle Aged
Prospective Studies
Quality of Life
Registries
SARS-CoV-2
Surveys and Questionnaires
Treatment Outcome

Semantics

Type Source Name
drug DRUGBANK Oxygen
disease MESH long COVID
disease MESH infection
disease MESH chronic condition
disease MESH SARS CoV 2 infection
disease MESH autoimmunity
disease MESH abnormalities
disease MESH mitochondrial dysfunction
disease IDO symptom
disease IDO intervention
disease MESH diabetic foot
disease MESH ulcers
disease MESH emergency
disease IDO blood
disease MESH clinical relevance
drug DRUGBANK Coenzyme M
disease MESH contraindications
drug DRUGBANK Medical air
disease MESH osteomyelitis
disease IDO quality
disease MESH general health
disease MESH anxiety
disease MESH depression
disease MESH re infection
disease IDO history

Original Article

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *